Company Overview
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Why Investors Should Care
Generates a return on equity of 116.0%, reflecting efficient use of shareholder capital.
Trades at a P/E of 1.0, below the sector median of 24.8.
Carries low leverage with a debt-to-equity ratio of 0.26.
Recent Developments
- Dec 2025 Revenue of $63.26M (+9.7% YoY); net profit $6.82M.
- Trailing 12 Months Year-on-year growth — revenue +14.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.77% |
| 1 Year: | 14.00% |
Stock Price Performance
| 1 Year: | +40.41% |
| 6 Months: | -19.58% |
| 3 Months: | -4.91% |
| 1 Month: | +1.50% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.22 · Neutral
P/E of 0.98 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 116.0%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 38.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FBIO Fortress Biotech, Inc. PHARMA | 2.71 | 0.98 | $90.38M | 0.00% | -51.71% | 115.98% | 6.77% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | - | 500.00K | 0 | 25.00K | - | - | 2.23M | 975.00K | - | 2.78M | 4.40M | 2.52M | 7.54M | 5.90M | 6.82M | 5.17M | 8.99M | 6.48M | 9.25M | 9.77M | 12.92M | 9.46M | 9.47M | 11.59M | 17.84M | 21.09M | 23.93M | 18.89M | 16.53M | 12.43M | 17.39M | 34.75M | 13.03M | 14.90M | 14.63M | 13.14M | 16.41M | 17.63M | 16.04M |
| Gross Profit | - | - | - | 0 | 25.00K | - | - | 1.91M | 934.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -4.35M | -4.96M | -12.57M | -7.76M | -18.10M | -12.96M | -15.57M | -17.04M | -17.18M | -32.22M | -19.12M | -25.50M | -31.80M | -30.62M | -34.17M | -25.40M | -28.20M | -41.21M | -32.61M | -25.29M | -22.54M | -21.53M | -25.40M | -23.04M | -30.02M | -42.86M | -49.92M | -47.27M | -50.93M | -50.73M | -58.87M | -50.10M | -13.76M | -36.57M | -27.79M | -22.09M | -22.32M | -36.47M | -6.81M | -7.74M |
| Net Income | -4.59M | -3.71M | -12.06M | -6.17M | -18.16M | -12.04M | -12.21M | -12.48M | -12.98M | -17.43M | -11.98M | -17.36M | -27.12M | -10.41M | -21.02M | -21.61M | -16.64M | -24.88M | 1.39M | -13.10M | -12.76M | -12.37M | -13.31M | -15.55M | -8.82M | -3.54M | -20.78M | -15.76M | -21.36M | -22.51M | -21.54M | -24.78M | -5.04M | -15.42M | -10.95M | -12.87M | -10.58M | 15.49M | 5.85M | 110.37M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.49 | - | - | - | 0.02 | - | - | -0.19 | - | - | -0.11 | -0.04 | -0.26 | -0.18 | -0.26 | -4.11 | -0.21 | -3.65 | -0.94 | -1.04 | -0.73 | -0.76 | -0.48 | 0.45 | 0.11 | 2.82 |
| R&D Expense | 1.61M | - | 1.64M | 2.41M | 9.07M | - | 7.74M | 6.35M | 7.32M | - | 8.40M | - | - | - | 24.96M | - | - | - | 23.27M | - | - | 15.12M | 17.27M | 13.76M | 20.15M | 33.83M | 28.08M | 36.72M | 33.13M | 29.90M | 39.51M | 32.14M | 20.35M | 24.84M | 12.67M | 9.45M | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 863.00K | 16.48M | 17.25M | 26.88M | 36.63M | 45.60M | 68.79M | 75.74M | 84.51M | 57.67M | 63.26M |
| Operating Income | - | - | -2.61M | -9.24M | -35.04M | -27.18M | -35.78M | -20.65M | -50.53M | -65.71M | -89.80M | -120.00M | -110.82M | -94.27M | -188.54M | -203.56M | -142.34M | -110.38M | -70.22M |
| Net Income | -2.64M | -3.80M | -3.67M | -9.98M | -36.36M | -27.61M | -37.16M | -20.39M | -48.43M | -55.09M | -66.88M | -84.15M | -39.96M | -46.53M | -64.70M | -86.58M | -60.64M | -46.00M | 6.82M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.79 | -15.97 | -8.47 | -2.69 | -0.07 |
| R&D Expense | - | - | 2.27M | 8.34M | 8.58M | 17.47M | 25.68M | 10.24M | 29.81M | 35.13M | 48.32M | 87.38M | 81.33M | 64.11M | 128.87M | 134.88M | 106.07M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2006 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | 14.94M | 23.38M | 40.99M | 100.58M | 89.33M | 118.61M | 170.73M | 245.95M | 140.99M | 226.42M | 333.41M | - | 294.30M | 167.53M | 144.22M | 185.55M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 230.43M | 117.02M | 90.37M | 123.84M |
| Cash & Equivalents | 0 | - | - | 7.00K | 1.51M | 14.86M | 23.16M | 40.20M | 99.52M | 49.76M | 98.18M | 88.29M | 94.95M | 65.51M | 136.86M | 233.35M | - | 178.27M | 80.93M | 57.26M | 79.38M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.16M | 10.21M | 14.43M | 9.62M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.21M | 15.22M | 10.23M | 29.78M |
| Total Liabilities | - | - | - | - | - | 1.56M | 4.24M | 18.96M | 19.30M | 18.80M | 34.34M | 87.76M | 125.45M | 121.25M | 153.89M | 136.41M | - | 244.28M | 165.94M | 145.87M | 123.36M |
| Current Liabilities | - | - | - | - | - | 1.56M | 3.49M | 5.13M | 11.21M | 4.08M | 10.58M | 56.56M | 71.44M | 55.61M | 45.62M | 51.76M | - | 127.72M | 84.91M | 71.40M | 49.74M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | 14.01M | 24.01M | 30.22M | 67.54M | 84.41M | 84.66M | 51.68M | - | 93.14M | 60.86M | 57.96M | 59.50M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 127.34M | 84.66M | 75.96M | 74.30M |
| Total Equity | 0 | -123.00K | -2.75M | 5.00K | -15.90M | -15.90M | 19.13M | 22.03M | 81.28M | 70.52M | 56.85M | 38.49M | 52.57M | 1.85M | 26.21M | 100.34M | - | 41.72M | 22.54M | 22.74M | 49.87M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.37M | 15.09M | 27.91M | 31.36M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.35M | -5.68M | -10.95M | -23.19M | -29.65M | - | -20.38M | -45.81M | -81.31M | -98.85M | -94.96M | -83.68M | -116.54M | -179.40M | -128.22M | -80.19M | -65.78M |
| Investing Cash Flow | -2.00K | -13.00K | -3.84M | -279.00K | -188.00K | - | 7.88M | -6.06M | -40.22M | 18.82M | 20.10M | -7.16M | 40.51M | -22.93M | -2.10M | -15.00M | 10.12M |
| Financing Cash Flow | 3.86M | 19.04M | 23.09M | 40.51M | 89.16M | - | 60.92M | 42.91M | 150.38M | 50.65M | 146.71M | 172.41M | 148.99M | 75.32M | 32.74M | 70.64M | 77.44M |
| Capital Expenditure | - | - | -0 | -54.00K | -40.00K | -0 | -283.00K | -6.37M | -648.00K | -7.08M | -2.35M | -1.93M | -4.57M | -2.71M | -63.00K | -0 | - |
| Free Cash Flow | - | - | -10.95M | -23.25M | -29.69M | - | -20.66M | -52.18M | -81.95M | -105.93M | -97.31M | -85.61M | -121.11M | -182.12M | -128.29M | -80.19M | - |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | 0 | 70.00K | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | -5,855.3% | -398.7% | -520.7% | -446.4% | -302.5% | -206.7% | -274.1% | -268.8% | -168.4% | -191.4% | -111.0% |
| Net Margin % | - | - | - | - | - | - | - | - | -5,611.6% | -334.3% | -387.8% | -313.0% | -109.1% | -102.0% | -94.1% | -114.3% | -71.7% | -79.8% | 10.8% |
| ROE % | 96.2% | -75,980.0% | 23.1% | 62.8% | -190.0% | -125.3% | -45.7% | -28.9% | -85.2% | -143.1% | -127.2% | -4,543.6% | -152.4% | -46.4% | - | -207.5% | -269.0% | -202.3% | 13.7% |
| ROCE % | - | - | - | -69.1% | -176.3% | -75.8% | -40.0% | -24.2% | -46.8% | -57.6% | -51.5% | -140.5% | -61.3% | -33.5% | - | -122.2% | -172.3% | -151.6% | -51.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.11% | 1.04M | $2.60M |
| 2 | Opaleye Management Inc. | 2.67% | 890.00K | $2.23M |
| 3 | Mackenzie Financial Corporation | 1.67% | 555.68K | $1.39M |
| 4 | GSA Capital Partners LLP | 1.37% | 458.47K | $1.15M |
| 5 | Shikiar Asset Management, Inc. | 0.92% | 305.47K | $766.73K |
| 6 | Geode Capital Management, LLC | 0.90% | 300.52K | $754.31K |
| 7 | Blackrock Inc. | 0.67% | 224.78K | $564.20K |
| 8 | Two Sigma Investments, LP | 0.64% | 213.79K | $536.60K |
| 9 | Bridgeway Capital Management, LLC | 0.53% | 177.37K | $445.19K |
| 10 | Vanguard Fiduciary Trust Co | 0.50% | 166.37K | $417.59K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FBIO
Fortress Biotech's business presentation goes online Sept. 11 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNT255VndJamRWYTV0WE44LW84MVJfZFhBdFJyY2tORzRrRnNpLV90aWdfbllkM3RzQ2ZtTEJLVS1USVJEaUZUY3dteDNJa3l2Q19Sd2U5dFdVc3ZrZHNHemh6QmEwbHFkVFd6Q3RWeG15TEVhWml4RVhySHFMQzE4Xy16c1ZWcVY0V0MyMV…
FBIO - Fortress Biotech Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFA3VDJyTUJRLUZnSW5FUW9JeGlGdzJNblVYVm1kTVE4d3VENXlYMUZaZ1hIWTBTNGp0YVZUZm03SmRDOEhDQ3c?oc=5" target="_blank">FBIO - Fortress Biotech Inc Stock Price and Quote</a> <font c…
FBIO Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5NS2tmWUV4YS11WlloZXRFVGlwTWpzVUkteGppbVNvcWpSMV8xTE5zSTdtc2RfV2ZmQk1ZWFRHcWh6MEZudTh4NnM3M1BYS044dkNiY3lWY2xsRXNselFGQndEVG5ZYTV5OXVWRUFEV0RWWnFNcGY1LURn?oc=5" target="_blank">FBI…
FBIO | Fortress Biotech, Inc. Financials - Revenue Breakdown - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5nVHk0cmgtMHlDUnhmZzFuMWJRLWhOZDd5clVMeERjMTlaRllaVzFnSkNVZnR6b3EtSF9WQ2QxUXZHWlkwdGh1UFFlelk1T3B3OGRfUTVsRVdDejRvbG5kVzZxOW5BZnByNlNtWU9qTEtNLWw0U1cw?oc=5" target="_blank">FBIO | …
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxObXJNZEpJcGJ2RTViLWNNS2JfWWV5Q2xlRVh3OVdrWkQzQ190TEM1MzhhbllFMm9hWlBSZEo0R1BHS0xKRHBzZlg4ak5PV3d5a1ozNkZ2cjNQYzk5c21CYldaMjBuSXZwS0FudnNtQkQzTnhuUzRSN0tKM3U0cVRxcEZieDk?oc=5" targ…
Fortress Biotech Just Netted $159 Million - Its Preferred Shares Could Be The Real Winner - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQbTNoeG16RGdmSEhHaTFQeUM3Ull6ZUpfUzVlaGlWVHVfTDVkY0pxN0xMNW5jbmtNNmxadHVFcjNacTJRa2pFTEtlUTZCWks5T3M2Y2hobVdYUXZwRVBfOVM4Tm1PRUx6dFlRc3U3c0FVUmRaQnFiZU5ZWFZVb3FSMlFpZjVQQ1oyWUF6cT…
FBIO — Frequently Asked Questions
What is the current share price of Fortress Biotech, Inc. (FBIO)?
As of 2026-09-19 21:16 PDT, Fortress Biotech, Inc. (FBIO) trades at $2.71 on NasdaqCM. Its 52-week range is $1.93 to $4.38.
What is the market capitalisation of FBIO?
Fortress Biotech, Inc. (FBIO) has a market capitalisation of $90.38M on NasdaqCM.
What is the P/E ratio of FBIO?
FBIO trades at a trailing price-to-earnings (P/E) ratio of 0.98. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.53.
What is the return on equity (ROE) of FBIO?
FBIO has a return on equity (ROE) of 115.98%. Its return on capital employed (ROCE) is -51.71%.
Is FBIO a good stock to buy?
This page provides a data-driven analysis of Fortress Biotech, Inc. (FBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.